Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 9.10 9.00 9.20 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 6.1 -9.5 3.0 3.0 38

Yourgene Health PLC DPYD screening recommended in Spain

18/11/2021 7:00am

RNS Non-Regulatory


Yourgene Health PLC

18 November 2021

Yourgene Health plc

("Yourgene" or the "Company")

DPYD screening recommended in Spain

Follows recommendations in Germany, Wales, England and Belgium

Manchester, UK - 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes the publication in Clinical and Translational Oncology, titled: ' Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fuoropyrimidines(1) ', which highlights the benefits of using a DPYD genotyping test to help identify cancer patients with Dihydropyrimidine Dehydrogenase ( DPD) deficiency prior to treatment with the chemotherapeutic drug 5-Fluorouracil (5-FU).

5 -FU is a widely used chemotherapy agent in the treatment of cancers, however for some patients who suffer from DPD deficiency 5-FU administered at normal therapeutic doses can cause severe and sometimes lethal side effects. T his review is welcomed by Yourgene as representatives of the Spanish Pharmacogenetics and Pharmacogenomics Society ('SEFF') and the Spanish Society of Medical Oncology ('SEOM'), provided the consensus opinion that: "in the current era of personalized medicine, it is highly recommended to genotype DPYD polymorphisms before administering fuoropyrimidines."

Yourgene launched the Elucigene(R) DPYD assay, used to detect the four most clinically relevant DPYD mutations, back in September 2019, and has already welcomed the screening recommendations in Germany, Wales, NHS England and Belgium. An estimated two million people globally are treated with fluoropyrimidines (including 5-FU) each year(2) , with between 10-30% of these patients suffering severe side effects associated with DPD deficiency(3) . The screening enables clinicians to reduce the risk of increased toxicity from 5-FU exposure in these patients by treatment with a lower dose, or alternate drug therapy where indicated.

Lyn Rees, CEO of Yourgene, commented: "We are thrilled to see DPYD screening recognised once again, this time in Spain by representatives of SEFF and SEOM. We look forward to working closely with our established distribution partner in the region, Diagnostica Longwood, to support DPYD screening across labs in Spain. By looking at how genes impact upon a patient's response to drugs, personalised medicine is at the forefront of our healthcare systems more than ever before, and we are pleased Yourgene is supporting this progression within the oncology market."


1 -

2 - D. Meulendijks et al./Cancer Treatment Reviews 50 (2016) 23-34

3 - Cancer Research UK

Yourgene Health plc                                                   Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                      
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
Singer Capital Markets (Joint Corporate                               Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George 
Stifel Nicolaus Europe Limited (Joint                                 Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
Walbrook PR Ltd (Media and Investor        Tel: +44 (0)20 7933 8780 or 
Paul McManus / Lianne Applegarth                            Mob: 07980 541 893 / 07584 391 303 
 / Alice Woodings                                                              / 07407 804 654 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit and follow us on twitter @Yourgene_Health.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 18, 2021 02:00 ET (07:00 GMT)

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221006 05:27:33